ABBVIE INC. vs. Akari Therapeutics plc ADR (0.01 USD)
ABBVIE INC. (ABBV) comes out ahead, leading on 5 of 5 compared factors.
Size & Scale
| ABBV | AKTX | |
|---|---|---|
| Market Cap | $466.55 billion | $17.83 million |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | $-30,960,000 |
ABBV leads on 2 of 2 size & scale factors.
Valuation
| ABBV | AKTX | |
|---|---|---|
| P/E Ratio | 74.71 | — |
| Price / Book | -79.24 | 0.96 |
| Price / Sales | 7.25 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | AKTX | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | -166.50% |
ABBV leads on 1 of 1 profitability factors.
Dividend
| ABBV | AKTX | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and AKTX split the dividend factors evenly.
Risk & Sentiment
| ABBV | AKTX | |
|---|---|---|
| Short Interest | 0.85% | 30.21% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, AKTX overview, AKTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.